
Guard Therapeutics Intl Investor Relations Material
Latest events

R&D Update
Guard Therapeutics Intl

Q1 2025
5 May, 2025

Q4 2024
20 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Guard Therapeutics Intl
Access all reports
Guard Therapeutics International AB is a Swedish biopharmaceutical company focused on the development of therapies for the diagnosis and treatment of acute kidney injuries. The company is most known for its investigational drug, ROSGard, a biological candidate designed to prevent kidney damage by mimicking the body's defense system against oxidative stress, thereby protecting, cleaning, and repairing exposed cells and tissues. Guard Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq First North.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
GUARD
Country
🇸🇪 Sweden